Eisai to Launch Alzheimer’s Drug Leqembi in Japan on 20th

Thu Dec 14 2023
icon-facebook icon-twitter icon-whatsapp

TOKYO: Eisai announced that its Alzheimer’s medication, Leqembi, is set to launch in Japan on December 20, following its inclusion in the National Health Insurance price list.

The intravenous treatment, developed in collaboration with US partner Biogen, will incur a cost of approximately 2.98 million yen ($20,438) per patient per year, in accordance with a ruling from a Japanese health ministry panel issued on the same day.

CEO Haruo Naito, during a briefing, revealed that the anticipated peak annual sales for Leqembi are projected to reach 98.6 billion yen ($676.22 million). The drug, which received approval from Japanese regulators in September, is priced at around $26,500 in the United States, where it obtained full approval in July.

Eisai has ambitious targets, aiming to have 4,000-5,000 patients on Leqembi in Japan by fiscal 2024. Meanwhile, in the United States, the company anticipates reaching 10,000 patients by the end of March.

Leqembi, an antibody specifically designed to eliminate the sticky deposits of the protein amyloid beta in the brains of Alzheimer’s patients, represents a groundbreaking development. It is the first treatment demonstrated to slow the progression of the disease in individuals in the earlier stages of Alzheimer’s.

 

 

icon-facebook icon-twitter icon-whatsapp